Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178657 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hyeyoung Hailey Yoon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auc…. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Macrophages, Immune System Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 388 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, University of Auckland, University of Auckland Doctoral Scholarship.
Abstract (Originalsprache)
Macrophages are essential for immune homeostasis, playing crucial roles in immune responses from initiation to resolution. They trigger acute inflammation to promote elimination of pathogens and regulate excessive immune reactions to prevent chronic inflammation and autoimmune diseases. Consequently, macrophage dysfunction contributes to the progression of many disorders that involve inflammation. Cannabinoid Receptor 2 (CB2) has emerged as a promising therapeutic target due to its role in regulating macrophage-mediated immune functions, including via modulation of cytokine secretion, migration, phagocytosis, and polarisation. CB2 activation can produce beneficial outcomes via suppressing macrophage-mediated inflammatory pathways in animal models for various diseases that involve acute or chronic central or peripheral inflammation, whereas blocking CB2 may have utility when macrophage polarisation to a “resolving” phenotype is deleterious, such as in tumour-associated macrophages. However, despite abundant promising preclinical results, the relatively few CB2-selective agonists tested in clinical trials to date have exhibited limited efficacy. Here, we provide an overview of the roles of macrophages in health and disease, thoroughly review in vitro and in vivo preclinical findings on CB2-mediated modulation of macrophage function, summarise current progress in clinical trials for CB2-targeted compounds, and discuss approaches for addressing current challenges in ongoing efforts toward developing safe and effective CB2-targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1142, New Zealand.
ORCID-Profile: Hyeyoung Hailey Yoon, Natasha Lillia Grimsey
Förderung
- Health Research Council of New Zealand
- University of Auckland
- University of Auckland Doctoral Scholarship
- Health Research Council of New Zealand Sir Charles Hercus Health Research Fellowship
Zitieren
APA
Yoon, H. H., & Grimsey, N. L. (2025). Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178657
Vancouver
Yoon HH, Grimsey NL. Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178657
BibTeX
@article{Yoon2025,
author = {Yoon, Hyeyoung Hailey and Grimsey, Natasha Lillia},
title = {Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178657}
}
EUVIMED